| scholarly article | Q13442814 |
| P50 | author | Pallab Maity | Q47975156 |
| Sumanta Dey | Q80979023 | ||
| P2093 | author name string | Uday Bandyopadhyay | |
| Athar Alam | |||
| Chinmay Pal | |||
| Manish Goyal | |||
| Mohd Shameel Iqbal | |||
| Samik Bindu | |||
| P2860 | cites work | Malaria in 2002 | Q21032486 |
| The economic and social burden of malaria | Q21032507 | ||
| Erythrocyte G protein as a novel target for malarial chemotherapy | Q21144682 | ||
| HDP-a novel heme detoxification protein from the malaria parasite | Q21559501 | ||
| Human glutathione transferase A4-4 crystal structures and mutagenesis reveal the basis of high catalytic efficiency with toxic lipid peroxidation products | Q22010032 | ||
| Identification of an antimalarial synthetic trioxolane drug development candidate | Q22061876 | ||
| Artemisinins target the SERCA of Plasmodium falciparum | Q22061877 | ||
| 1,2-dithiole-3-ones as potent inhibitors of the bacterial 3-ketoacyl acyl carrier protein synthase III (FabH) | Q24564306 | ||
| Inhibition of Plasmodium falciparum choline kinase by hexadecyltrimethylammonium bromide: a possible antimalarial mechanism | Q24675578 | ||
| MINT: the Molecular INTeraction database | Q24675827 | ||
| Similarities and differences in genome-wide expression data of six organisms | Q24800747 | ||
| RAP1 controls rhoptry targeting of RAP2 in the malaria parasite Plasmodium falciparum | Q27230048 | ||
| Release of sequestered malaria parasites upon injection of a glycosaminoglycan | Q27320094 | ||
| Insights into antifolate resistance from malarial DHFR-TS structures | Q27641016 | ||
| Structural and Functional Relationships in the Virulence-associated Cathepsin L Proteases of the Parasitic Liver Fluke, Fasciola hepatica | Q27649433 | ||
| Structural basis for the inhibition of the essential Plasmodium falciparum M1 neutral aminopeptidase | Q27653672 | ||
| Mutations in dihydropteroate synthase are responsible for sulfone and sulfonamide resistance in Plasmodium falciparum | Q27861947 | ||
| A Plasmodium falciparum dipeptidyl aminopeptidase I participates in vacuolar hemoglobin degradation | Q27972584 | ||
| Roles for two aminopeptidases in vacuolar hemoglobin catabolism in Plasmodium falciparum | Q27972941 | ||
| Plasmodium hemozoin formation mediated by histidine-rich proteins | Q27972955 | ||
| Critical role of a K+ channel in Plasmodium berghei transmission revealed by targeted gene disruption | Q36608978 | ||
| P. falciparum dihydrofolate reductase and dihydropteroate synthase mutations: epidemiology and role in clinical resistance to antifolates | Q36648400 | ||
| Antimalarial drugs inhibiting hemozoin (beta-hematin) formation: a mechanistic update | Q36678059 | ||
| Molecular Cloning of CTP: Phosphocholine Cytidylyltransferase from Plasmodium falciparum | Q36684908 | ||
| Isoprenoid biosynthesis of the apicoplast as drug target | Q36723914 | ||
| Novel molecular targets for antimalarial chemotherapy | Q36752434 | ||
| Nucleoside transport as a potential target for chemotherapy in malaria | Q36754629 | ||
| The sensitivity of Plasmodium protein synthesis to prokaryotic ribosomal inhibitors | Q36847579 | ||
| Helicases - feasible antimalarial drug target for Plasmodium falciparum | Q36933788 | ||
| Exploring functional genomics for drug target and therapeutics discovery in Plasmodia | Q37033366 | ||
| Coenzyme A biosynthesis: an antimicrobial drug target | Q37049372 | ||
| The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs | Q37066163 | ||
| Assessing the polyamine metabolism of Plasmodium falciparum as chemotherapeutic target. | Q37153904 | ||
| Type II fatty acid synthesis is essential only for malaria parasite late liver stage development | Q37208067 | ||
| Mitochondria in malaria and related parasites: ancient, diverse and streamlined. | Q37278195 | ||
| Identification of a metabolically stable triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with antimalarial activity in mice | Q37352712 | ||
| Prodrugs of bisthiazolium salts are orally potent antimalarials | Q37585368 | ||
| Plasmodium falciparum signal peptide peptidase is a promising drug target against blood stage malaria | Q37649200 | ||
| Thymidylate synthase-dihydrofolate reductase in protozoa | Q37905656 | ||
| Molecular mechanism for switching of P. falciparum invasion pathways into human erythrocytes | Q38321747 | ||
| Kinetic and biochemical characterization of Plasmodium falciparum GMP synthetase | Q27973021 | ||
| Functional characterization and target validation of alternative complex I of Plasmodium falciparum mitochondria | Q27973427 | ||
| Cyclin H activation and drug susceptibility of the Pfmrk cyclin dependent protein kinase from Plasmodium falciparum | Q27973602 | ||
| Localization of the Plasmodium falciparum PfNT1 nucleoside transporter to the parasite plasma membrane | Q27973846 | ||
| A subset of Plasmodium falciparum SERA genes are expressed and appear to play an important role in the erythrocytic cycle | Q27974188 | ||
| Glutathione S-transferase of the malarial parasite Plasmodium falciparum: characterization of a potential drug target | Q27974461 | ||
| The initiating steps of a type II fatty acid synthase in Plasmodium falciparum are catalyzed by pfACP, pfMCAT, and pfKASIII | Q27974582 | ||
| Plasmodium falciparum protein kinase 5 and the malarial nuclear division cycles | Q27976464 | ||
| Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as antimalarial drugs | Q28143905 | ||
| The apicoplast as an antimalarial drug target | Q28214224 | ||
| The catalytic mechanism and structure of thymidylate synthase | Q28290270 | ||
| Deletion of the parasite-specific insertions and mutation of the catalytic triad in glutathione reductase from chloroquine-sensitive Plasmodium falciparum 3D7 | Q28377536 | ||
| A plant-derived morphinan as a novel lead compound active against malaria liver stages | Q28469086 | ||
| Drug development papers in PLoS Medicine: how we try to spot a winner | Q28469092 | ||
| Safety and efficacy of methylene blue combined with artesunate or amodiaquine for uncomplicated falciparum malaria: a randomized controlled trial from Burkina Faso | Q28472182 | ||
| Evolutionary patterning: a novel approach to the identification of potential drug target sites in Plasmodium falciparum | Q28473999 | ||
| A gene-coexpression network for global discovery of conserved genetic modules | Q29614451 | ||
| Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance | Q29615118 | ||
| Invasion of red blood cells by malaria parasites | Q29618806 | ||
| Opportunities and Challenges in Antiparasitic Drug Discovery | Q29999214 | ||
| Intraerythrocytic Plasmodium falciparum expresses a high affinity facilitative hexose transporter | Q30039208 | ||
| Metabolic maps and functions of the Plasmodium mitochondrion | Q30039501 | ||
| Enzymes for heme biosynthesis are found in both the mitochondrion and plastid of the malaria parasite Plasmodium falciparum | Q30040491 | ||
| Nuclear-encoded proteins target to the plastid in Toxoplasma gondii and Plasmodium falciparum | Q30041439 | ||
| Subcellular localization and characterization of chorismate synthase in the apicomplexan Plasmodium falciparum | Q30041832 | ||
| Phenotypic variation of Plasmodium falciparum merozoite proteins directs receptor targeting for invasion of human erythrocytes | Q30042170 | ||
| A Plasmodium falciparum homologue of Plasmodium vivax reticulocyte binding protein (PvRBP1) defines a trypsin-resistant erythrocyte invasion pathway | Q30043024 | ||
| Subcellular discharge of a serine protease mediates release of invasive malaria parasites from host erythrocytes | Q30043441 | ||
| Recombinant Plasmodium falciparum reticulocyte homology protein 4 binds to erythrocytes and blocks invasion | Q30043667 | ||
| Molecular characterization of a 2-Cys peroxiredoxin from the human malaria parasite Plasmodium falciparum | Q30047901 | ||
| Triclosan offers protection against blood stages of malaria by inhibiting enoyl-ACP reductase of Plasmodium falciparum | Q30049704 | ||
| Tropical infectious diseases: metabolic maps and functions of the Plasmodium falciparum apicoplast | Q30080014 | ||
| Structural insights into the Plasmodium falciparum histone deacetylase 1 (PfHDAC-1): A novel target for the development of antimalarial therapy. | Q30368412 | ||
| Irreversible effect of cysteine protease inhibitors on the release of malaria parasites from infected erythrocytes | Q30494843 | ||
| Genetic complementation in apicomplexan parasites | Q30701283 | ||
| Channels and transporters as drug targets in the Plasmodium-infected erythrocyte | Q35639409 | ||
| Plasmodium falciparum thioredoxins and glutaredoxins as central players in redox metabolism | Q35666792 | ||
| Ferriprotoporphyrin IX, phospholipids, and the antimalarial actions of quinoline drugs | Q35669039 | ||
| Targeting ion channels of Plasmodium falciparum-infected human erythrocytes for antimalarial development | Q35698879 | ||
| Oxidative stress in malaria parasite-infected erythrocytes: host-parasite interactions | Q35704960 | ||
| Fatty Acid synthesis as a target for antimalarial drug discovery. | Q36047933 | ||
| Parasite plastids: approaching the endgame | Q36052586 | ||
| Free heme toxicity and its detoxification systems in human | Q36139710 | ||
| Functional conservation of the malaria vaccine antigen MSP-119across distantly related Plasmodium species | Q47857319 | ||
| Plasmodium falciparum: isolation and characterisation of a gene encoding protozoan GMP synthase | Q47857723 | ||
| A voltage-dependent channel involved in nutrient uptake by red blood cells infected with the malaria parasite | Q47871147 | ||
| Design and synthesis of amidoxime derivatives for orally potent C-alkylamidine-based antimalarial agents. | Q47891646 | ||
| Oxindole-based compounds are selective inhibitors of Plasmodium falciparum cyclin dependent protein kinases | Q47934737 | ||
| Cell volume control in the Plasmodium-infected erythrocyte | Q47972623 | ||
| Haem polymerization in malaria | Q47998079 | ||
| The methionine synthesis cycle and salvage of methyltetrahydrofolate from host red cells in the malaria parasite (Plasmodium falciparum). | Q48020701 | ||
| Inhibition of Plasmodium falciparum hypoxanthine-guanine phosphoribosyltransferase mRNA by antisense oligodeoxynucleotide sequence | Q48020981 | ||
| Kinetic characterization of Na+/H+ antiport of Plasmodium falciparum membrane | Q48021291 | ||
| Antimalarial activity of molecules interfering with Plasmodium falciparum phospholipid metabolism. Structure-activity relationship analysis | Q48037569 | ||
| Excess hemoglobin digestion and the osmotic stability of Plasmodium falciparum-infected red blood cells. | Q52024420 | ||
| Purification and properties of Plasmodium falciparum malate dehydrogenase | Q54279115 | ||
| Inhibiting enoyl-ACP reductase (FabI) across pathogenic microorganisms by linear sesquiterpene lactones from Anthemis auriculata. | Q54423737 | ||
| Physcomitrella and Arabidopsis: the David and Goliath of reverse genetics | Q55872486 | ||
| Characterisation of the gene encoding adenylosuccinate lyase of Plasmodium falciparum1Note: Nucleotide sequence data reported in this paper available in the GenBank™ data base under the accession number U84403.1 | Q56567665 | ||
| A nutrient-permeable channel on the intraerythrocytic malaria parasite | Q59086409 | ||
| Heat shock protein 90 function is essential for Plasmodium falciparum growth in human erythrocytes. | Q38357729 | ||
| Sulfated cyclodextrins inhibit the entry of Plasmodium into red blood cells. Implications for malarial therapy | Q38955846 | ||
| Structure-activity relationships for antiplasmodial activity among 7-substituted 4-aminoquinolines. | Q38965197 | ||
| Recombinant Plasmodium falciparum glutathione reductase is inhibited by the antimalarial dye methylene blue | Q39014575 | ||
| Peptidomimetic inhibitors of protein farnesyltransferase show potent antimalarial activity | Q39318586 | ||
| Identification of additional rRNA fragments encoded by the Plasmodium falciparum 6 kb element | Q39718842 | ||
| Chemosensitization of Plasmodium falciparum by probenecid in vitro | Q39776217 | ||
| In vivo antimalarial activities of mono- and bis quaternary ammonium salts interfering with Plasmodium phospholipid metabolism | Q39792613 | ||
| A class of potent antimalarials and their specific accumulation in infected erythrocytes | Q40750735 | ||
| H+-coupled pantothenate transport in the intracellular malaria parasite. | Q40816708 | ||
| The mode of action of the antimalarial artemisinin and its derivatives | Q41148700 | ||
| Unraveling the mode of action of the antimalarial choline analog G25 in Plasmodium falciparum and Saccharomyces cerevisiae | Q41269199 | ||
| Plasmodium falciparum purine nucleoside phosphorylase is critical for viability of malaria parasites | Q41771473 | ||
| Involvement of delta-aminolaevulinate synthase encoded by the parasite gene in de novo haem synthesis by Plasmodium falciparum | Q41824191 | ||
| Antimalarial activity of phenylthiazolyl-bearing hydroxamate-based histone deacetylase inhibitors | Q41838047 | ||
| Antiplasmodial activity of [(aryl)arylsulfanylmethyl]Pyridine | Q41886196 | ||
| Synthesis and evaluation of new antimalarial phenylurenyl chalcone derivatives | Q41912288 | ||
| Novel short chain chloroquine analogues retain activity against chloroquine resistant K1 Plasmodium falciparum | Q41916719 | ||
| Ferriprotoporphyrin IX fulfills the criteria for identification as the chloroquine receptor of malaria parasites | Q41926939 | ||
| The efficacy of benzimidazole drugs against Plasmodium falciparum in vitro | Q41927133 | ||
| Malarial haemozoin/beta-haematin supports haem polymerization in the absence of protein | Q41933334 | ||
| Quinoline anti-malarial drugs inhibit spontaneous formation of beta-haematin (malaria pigment). | Q41934645 | ||
| Synthesis of novel thiourea, thiazolidinedione and thioparabanic acid derivatives of 4-aminoquinoline as potent antimalarials | Q41938749 | ||
| Overcoming drug resistance to heme-targeted antimalarials by systematic side chain variation of 7-chloro-4-aminoquinolines | Q41941261 | ||
| High antiplasmodial activity of novel plasmepsins I and II inhibitors. | Q41944053 | ||
| Localization of ferrochelatase in Plasmodium falciparum | Q42042589 | ||
| Isoprenoid biosynthesis as a target for antibacterial and antiparasitic drugs: phosphonohydroxamic acids as inhibitors of deoxyxylulose phosphate reducto-isomerase | Q42156581 | ||
| Plasmodium falciparum carbonic anhydrase is a possible target for malaria chemotherapy | Q42638709 | ||
| Re-evaluation of how artemisinins work in light of emerging evidence of in vitro resistance | Q43127250 | ||
| Rapid optimization of a peptide inhibitor of malaria parasite invasion by comprehensive N-methyl scanning | Q43148430 | ||
| Inhibitory monoclonal antibodies recognise epitopes adjacent to a proteolytic cleavage site on the RAP-1 protein of Plasmodium falciparum | Q43570770 | ||
| Intraerythrocytic Plasmodium falciparum utilizes only a fraction of the amino acids derived from the digestion of host cell cytosol for the biosynthesis of its proteins | Q43868723 | ||
| Identification and characterization of allophenylnorstatine-based inhibitors of plasmepsin II, an antimalarial target. | Q43883477 | ||
| Potent antimalarial and transmission-blocking activities of centanamycin, a novel DNA-binding agent | Q44140206 | ||
| De novo and salvage biosynthesis of pteroylpentaglutamates in the human malaria parasite, Plasmodium falciparum | Q44219537 | ||
| Enzymic, phylogenetic, and structural characterization of the unusual papain-like protease domain of Plasmodium falciparum SERA5. | Q44588572 | ||
| Erythrocyte G Protein-Coupled Receptor Signaling in Malarial Infection | Q44590989 | ||
| Delta-aminolevulinic acid dehydratase from Plasmodium falciparum: indigenous versus imported. | Q44669060 | ||
| Protein farnesyltransferase inhibitors exhibit potent antimalarial activity | Q44713096 | ||
| Reticulocyte-binding protein homologue 1 is required for sialic acid-dependent invasion into human erythrocytes by Plasmodium falciparum | Q45197048 | ||
| Pyrimidine biosynthesis in parasitic protozoa: purification of a monofunctional dihydroorotase from Plasmodium berghei and Crithidia fasciculata. | Q46011810 | ||
| Selective inhibition of Pfmrk, a Plasmodium falciparum CDK, by antimalarial 1,3-diaryl-2-propenones | Q46105200 | ||
| Roles of 1-Cys peroxiredoxin in haem detoxification in the human malaria parasite Plasmodium falciparum | Q46407800 | ||
| Clotrimazole inhibits hemoperoxidase of Plasmodium falciparum and induces oxidative stress. Proposed antimalarial mechanism of clotrimazole | Q46465773 | ||
| An unprecedented twist to ODCase catalytic activity | Q46773972 | ||
| Resistance of Plasmodium falciparum field isolates to in-vitro artemether and point mutations of the SERCA-type PfATPase6. | Q46833947 | ||
| Bilirubin inhibits Plasmodium falciparum growth through the generation of reactive oxygen species | Q46857258 | ||
| Parasite mitochondria as a target of chemotherapy: inhibitory effect of licochalcone A on the Plasmodium falciparum respiratory chain | Q46875131 | ||
| A rhoptry antigen of Plasmodium falciparum contains conserved and variable epitopes recognized by inhibitory monoclonal antibodies | Q46949677 | ||
| Genomics-based drug design targets the AT-rich malaria parasite: implications for antiparasite chemotherapy | Q46959461 | ||
| Expression and activity of p67 are induced during heat shock | Q47680421 | ||
| S-adenosyl-L-homocysteine hydrolase as an attractive target for antimicrobial drugs | Q47834141 | ||
| Molecular cloning and characterization of a peroxiredoxin from the human malaria parasite Plasmodium falciparum | Q47834424 | ||
| An alternative model for heme biosynthesis in the malarial parasite | Q47846009 | ||
| Antibiotic inhibitors of organellar protein synthesis in Plasmodium falciparum | Q47854324 | ||
| pH regulation in the intracellular malaria parasite, Plasmodium falciparum. H(+) extrusion via a V-type H(+)-ATPase | Q47855660 | ||
| Mutations in the cytochrome b gene of Plasmodium berghei conferring resistance to atovaquone | Q30826460 | ||
| Rich-club phenomenon in the interactome of P. falciparum--artifact or signature of a parasitic life style? | Q30830693 | ||
| Antimalarial activity of new gossypol derivatives | Q30908680 | ||
| The plasmodium digestive vacuole: metabolic headquarters and choice drug target | Q33205197 | ||
| The pathway of hemoglobin degradation in malaria parasites | Q33207594 | ||
| Inhibitors of Plasmodium falciparum methionine aminopeptidase 1b possess antimalarial activity | Q33257977 | ||
| Identification of proteases that regulate erythrocyte rupture by the malaria parasite Plasmodium falciparum | Q33317962 | ||
| Inhibition of malaria parasite development by a cyclic peptide that targets the vital parasite protein SERA5. | Q33347981 | ||
| A systematic approach to understand the mechanism of action of the bisthiazolium compound T4 on the human malaria parasite, Plasmodium falciparum | Q33381401 | ||
| High throughput functional assays of the variant antigen PfEMP1 reveal a single domain in the 3D7 Plasmodium falciparum genome that binds ICAM1 with high affinity and is targeted by naturally acquired neutralizing antibodies | Q33432676 | ||
| An overview of chemotherapeutic targets for antimalarial drug discovery | Q33586646 | ||
| Targeting the fatty acid biosynthesis enzyme, beta-ketoacyl-acyl carrier protein synthase III (PfKASIII), in the identification of novel antimalarial agents | Q33605124 | ||
| Apicomplexan plastids as drug targets | Q33702247 | ||
| Enzymes of parasite thiol metabolism as drug targets | Q33730332 | ||
| Glutathione and trypanothione in parasitic hydroperoxide metabolism | Q33777935 | ||
| Peptide deformylase of eukaryotic protists: a target for new antiparasitic agents? | Q33868245 | ||
| Potent and selective activity of a combination of thymidine and 1843U89, a folate-based thymidylate synthase inhibitor, against Plasmodium falciparum | Q33979229 | ||
| Specific role of mitochondrial electron transport in blood-stage Plasmodium falciparum | Q34002708 | ||
| Synthesis and evaluation of cryptolepine analogues for their potential as new antimalarial agents. | Q34090100 | ||
| Mode of action and mechanisms of resistance for antimalarial drugs | Q34228129 | ||
| Large-scale analysis of 73 329 physcomitrella plants transformed with different gene disruption libraries: production parameters and mutant phenotypes | Q34420935 | ||
| Uncovering the molecular mode of action of the antimalarial drug atovaquone using a bacterial system. | Q34499482 | ||
| Hydrolysis of erythrocyte proteins by proteases of malaria parasites | Q34531043 | ||
| The thioredoxin system of Plasmodium falciparum and other parasites | Q34777950 | ||
| Band 3 is a host receptor binding merozoite surface protein 1 during thePlasmodium falciparuminvasion of erythrocytes | Q34982236 | ||
| Cyclin-dependent protein kinases as therapeutic drug targets for antimalarial drug development | Q35056015 | ||
| Validation of the hexose transporter of Plasmodium falciparum as a novel drug target. | Q35145816 | ||
| Potent inhibitors of Plasmodium phospholipid metabolism with a broad spectrum of in vitro antimalarial activities | Q35166107 | ||
| Specific inhibition of the plasmodial surface anion channel by dantrolene | Q35216701 | ||
| Why is the Plasmodium falciparum hexose transporter a promising new drug target? | Q35537890 | ||
| Molecular monitoring of Plasmodium falciparum resistance to artemisinin in Tanzania | Q35574214 | ||
| A blasticidin S-resistant Plasmodium falciparum mutant with a defective plasmodial surface anion channel | Q35612124 | ||
| Cytotoxic effect of curcumin on malaria parasite Plasmodium falciparum: inhibition of histone acetylation and generation of reactive oxygen species | Q35635984 | ||
| Synergistic interactions of the antiretroviral protease inhibitors saquinavir and ritonavir with chloroquine and mefloquine against Plasmodium falciparum in vitro. | Q35636034 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antimalarial | Q521616 |
| P304 | page(s) | 469-489 | |
| P577 | publication date | 2009-09-01 | |
| P1433 | published in | Expert Review of Clinical Pharmacology | Q15793519 |
| P1476 | title | Novel antimalarial drug targets: hope for new antimalarial drugs | |
| P478 | volume | 2 |
| Q40690139 | Antimalarial Activity of Small-Molecule Benzothiazole Hydrazones. |
| Q37334816 | Aspartic peptidases of human pathogenic trypanosomatids: perspectives and trends for chemotherapy. |
| Q35047048 | Development and validation of four Leishmania species constitutively expressing GFP protein. A model for drug discovery and disease pathogenesis studies |
| Q59100927 | Evaluation of in vitro antimalarial activity of different extracts of Artemisia aucheri Boiss. and A. armeniaca Lam. and fractions of the most potent extracts |
| Q27973678 | Identification and molecular characterization of an Alba-family protein from human malaria parasite Plasmodium falciparum |
| Q102053970 | Identification of a nuclear localization signal in the Plasmodium falciparum CTP: phosphocholine cytidylyltransferase enzyme |
| Q39369233 | In silico identification of promiscuous scaffolds as potential inhibitors of 1-deoxy-d-xylulose 5-phosphate reductoisomerase for treatment of Falciparum malaria |
| Q64062417 | Structural Insights Into Key Proteases as Therapeutic Drug Targets |
Search more.